IP protections threatened by Canadian reform bill, Industry warns
This article was originally published in Scrip
Executive Summary
The introduction of a new bill designed to reform Canada's Access to Medicines Regime (CAMR) would remove "almost all relevant protections on intellectual property", the president of Canada's Research-Based Pharmaceutical Companies (Rx&D) has warned.